| Not Yet Recruiting | CardioNETPOL National Registry of Carcinoid Heart Disease NCT07450287 | National Institute of Cardiology, Warsaw, Poland | — |
| Active Not Recruiting | Analysis of Optimal Treatment Sequencing of Surufatinib and Somatostatin Analogs in Neuroendocrine Tumors: A R NCT07534371 | West China Hospital | — |
| Recruiting | Study to Assess the Safety and Effectiveness of Novel Radiopharmaceutical Terbium-161 DOTATATE in Metastatic N NCT07404176 | Tata Memorial Hospital | Phase 2 |
| Not Yet Recruiting | Safety, Tolerability and Preliminary Efficacy of NEUK203-13 in Refractory Neuroendocrine Tumor Patients NCT07366658 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 1 |
| Not Yet Recruiting | 18F-AlF-NOTA-Octreotide PET in Neuroendocrine Neoplasms NCT07102056 | First Affiliated Hospital of Zhejiang University | — |
| Recruiting | Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment NCT07314164 | Ipsen | — |
| Recruiting | Sapu003 in Advanced mTOR-sensitive Solid Tumors NCT07369505 | SAPU NANO (US) LLC | Phase 1 |
| Recruiting | Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs. NCT07165132 | RayzeBio, Inc. | Phase 1 |
| Withdrawn | Neuroendocrine and Adrenal Tumors NCT04432532 | University of Pennsylvania | — |
| Recruiting | A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Othe NCT07129252 | Crinetics Pharmaceuticals Inc. | Phase 1 / Phase 2 |
| Recruiting | Prospective Multicenter Real-world Study of Surufatinib in Patients With Advanced Neuroendocrine Neoplasms NCT07272512 | Shanghai Zhongshan Hospital | Phase 4 |
| Recruiting | Study Assessing PET Imaging With Zirconium-labelled Girentuximab in Patients With HCC, ICC or NEN NCT06735560 | Nantes University Hospital | N/A |
| Recruiting | Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metast NCT04119024 | Anusha Kalbasi | Phase 1 |
| Recruiting | The Use of Guarana to Treat Fatigue in Patients With Neuroendocrine Tumors and Gynecologic Cancers (Guarana Fa NCT07151391 | University of Utah | Phase 2 |
| Recruiting | SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) o NCT06889493 | Peter Hosein, MD | Phase 1 |
| Recruiting | 18F Labeled FAP Targeted Molecular Probe in Early Tumor Diagnosis NCT06937112 | Nanjing First Hospital, Nanjing Medical University | — |
| Recruiting | Using Novel Imaging to More Safely Treat Neuroendocrine Tumors NCT06122610 | University of Wisconsin, Madison | Phase 1 |
| Recruiting | 61Cu-NODAGA-LM3 PET/CT for the Detection of Neuroendocrine Tumors (COPPER PET in NET) NCT06455358 | University Hospital, Basel, Switzerland | Phase 1 / Phase 2 |
| Recruiting | A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known NCT06805825 | Novelty Nobility, Inc. | Phase 1 |
| Not Yet Recruiting | Phase II Study of Adebrelimab, Chemotherapy, and Apatinib for Advanced Pulmonary Neuroendocrine Tumors NCT06764368 | Beijing Chest Hospital | Phase 2 |
| Recruiting | EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With NCT06263088 | Case Comprehensive Cancer Center | N/A |
| Completed | Correlation Between Body Composition and Pathologic Grade/Prognosis in GEP-NENs: A Retrospective Study NCT06983106 | Tongji Hospital | — |
| Recruiting | Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours NCT06345079 | Australasian Gastro-Intestinal Trials Group | Phase 2 |
| Not Yet Recruiting | Clinical-pathological Evaluation of Pit-NETs NCT06607198 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | — |
| Recruiting | Addressing Social Determinants of Health Among Metro Detroit Cancer Survivors NCT06908629 | Barbara Ann Karmanos Cancer Institute | N/A |
| Recruiting | Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies NCT06577987 | Circle Pharma | Phase 1 |
| Completed | EchoTip AcuCore Post-Market Clinical Study NCT06358001 | Cook Research Incorporated | — |
| Terminated | Comparison of Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Ne NCT05987176 | Imperial College London | Phase 2 |
| Recruiting | A Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tum NCT06505824 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 1 |
| Not Yet Recruiting | Evaluation of Study Experiences of Neuroendocrine Tumor Patients NCT05967481 | Power Life Sciences Inc. | — |
| Recruiting | Agnostic Therapy in Rare Solid Tumors NCT06638931 | Instituto do Cancer do Estado de São Paulo | Phase 2 |
| Active Not Recruiting | A Study of Etoposide-carboplatin in Combination With Pembrolizumab and Lenvatinib Maintenance in HG-NETs NCT06232564 | Imperial College London | Phase 2 |
| Not Yet Recruiting | Irinotecan Liposomes for the Treatment of Neuroendocrine Carcinoma NCT06485739 | First Affiliated Hospital Xi'an Jiaotong University | Phase 4 |
| Recruiting | Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with Long-acting Somatostatin Analogues - ATSA Tr NCT06855095 | The Netherlands Cancer Institute | Phase 2 / Phase 3 |
| Recruiting | A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and NCT06041516 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Study of the Value of hPG80 (Circulating Progastrin) for the Diagnosis of Neuroendocrine Tumours in Patients W NCT06430021 | Centre Hospitalier Universitaire Dijon | — |
| Enrolling By Invitation | A Pilot Study of Total-body PET Using FDA-approved Radiotracers Beyond 18F-FDG NCT05160480 | University of California, Davis | — |
| Active Not Recruiting | Defining Response Criteria for PET Scans for People With Neuroendocrine Tumors NCT06448208 | Memorial Sloan Kettering Cancer Center | — |
| Recruiting | A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Thera NCT06055439 | Chimeric Therapeutics | Phase 1 / Phase 2 |
| Not Yet Recruiting | Hyperthermia Enhanced Re-irradiation of Loco-regional Recurrent Tumors NCT04889742 | Charite University, Berlin, Germany | Phase 2 |
| Recruiting | 177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry NCT06395402 | University of Iowa | Phase 2 |
| Recruiting | Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors NCT06472388 | AC Camargo Cancer Center | Phase 2 |
| Recruiting | Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors NCT04090034 | Methodist Health System | — |
| Not Yet Recruiting | A Real-world Study of Octreotide Microspheres in Chinese Patients With Neuroendocrine Tumors NCT06300216 | Qilu Hospital of Shandong University | — |
| Recruiting | Clinical Application of the J-PET Scanner Prototype NCT06242119 | Jagiellonian University | — |
| Recruiting | Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring NCT05500391 | Centre Oscar Lambret | Phase 2 |
| Active Not Recruiting | Lipiodol Deposition Using Endhole vs. Pressure-Modulated Delivery NCT06204159 | Abramson Cancer Center at Penn Medicine | N/A |
| Recruiting | Influence of Tumour and Patient's Related Factors on the Response to Medical Treatments in Well Differentiated NCT06356467 | IRCCS San Raffaele | — |
| Active Not Recruiting | A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors NCT06148636 | David Bushnell | EARLY_Phase 1 |
| Unknown | Device Assisted Full Thickness Resection Versus Endoscopic Submucosal Dissection for Duodenal Neuroendocrine T NCT06121752 | Asian Institute of Gastroenterology, India | N/A |
| Recruiting | Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestin NCT05997056 | Aadi Bioscience, Inc. | Phase 2 |
| Recruiting | Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tu NCT05918302 | Grupo Espanol de Tumores Neuroendocrinos | Phase 3 |
| Not Yet Recruiting | Development of a Predictive Model for the Risk of Metastatic Disease in PPGLs, a Retrospective Cohort Study NCT04788927 | Rigshospitalet, Denmark | — |
| Recruiting | An Open, Single-center Clinical Study of Surufatinib Combined With Temozolomide and S-1 in the First-line Trea NCT06038461 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 1 / Phase 2 |
| Recruiting | Observational Study on GEP-and Pulm-NET Treated at FPG NCT06402695 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | — |
| Recruiting | "Receptor Radionuclide Therapy With 177Lu-DOTATOC NCT06045260 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Phase 2 |
| Recruiting | Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors NCT05746208 | University of California, San Francisco | Phase 2 |
| Terminated | A Study to Collect the Somatuline® Injector Device Preferences of Patients Living With Neuroendocrine Tumor (N NCT05922579 | Ipsen | — |
| Not Yet Recruiting | Phase II Study to Evaluate the Efficacy and Safety of 177Lu-Dotatate in the First-line Treatment of Patients W NCT05894486 | Peking University | Phase 2 |
| Recruiting | Comparison of Al18F-NOTA-LM3 With 68Ga-DOTATATE and 68Ga-NODAGA-LM3 PET/CT in Patients With Well-differentiate NCT06056362 | Peking Union Medical College Hospital | Phase 1 / Phase 2 |
| Recruiting | The Australia and New Zealand Multicentre Upper Gastrointestinal Endoscopic Tissue Resection Study NCT05804331 | Western Sydney Local Health District | — |
| Unknown | Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms NCT05709171 | Rigshospitalet, Denmark | Phase 2 |
| Withdrawn | 177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs NCT04915144 | British Columbia Cancer Agency | Phase 2 |
| Unknown | Biomarker Identification of Radionuclide Therapy-induced Radiation Responses NCT05513469 | Erasmus Medical Center | N/A |
| Active Not Recruiting | Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors NCT05249114 | Providence Health & Services | Phase 1 |
| Completed | Novel 99mTc-labeled Somatostatin Antaginosts in the Diagnostic Algotithm of Neuroendocrine Neoplasms NCT05871320 | Jagiellonian University | EARLY_Phase 1 |
| Unknown | GastroIntestinal Cancer in Children and Adolescents NCT05693519 | Paul G. Kemps, MD | — |
| Completed | Dual-Tracer Theranostic PET NCT05680675 | University of Utah | N/A |
| Recruiting | Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors. NCT05387603 | Lund University Hospital | Phase 3 |
| Active Not Recruiting | Lesion-to-lesion Comparison of 68Ga-HA-DOTATATE, 18F-DOPA, and 18F-FDG PET/CT in the Evaluation of Metastatic NCT05255159 | University of Alberta | Phase 2 |
| Recruiting | Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine NCT04086485 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Withdrawn | A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine NCT04614766 | David Bushnell | Phase 1 / Phase 2 |
| Recruiting | F-Tryptophan PET/CT in Human Cancers NCT05556473 | Barbara Ann Karmanos Cancer Institute | Phase 1 |
| Active Not Recruiting | A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GE NCT05459844 | Sinotau Pharmaceutical Group | Phase 3 |
| Recruiting | TARGETed Therapy Drug MONITOring in DIGestive Oncology NCT05443087 | UNICANCER | N/A |
| Unknown | 177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors NCT05475210 | Molecular Targeting Technologies, Inc. | Phase 1 |
| Recruiting | Improving Peptide Receptor Radionuclide Therapy With PARP Inhibitors NCT05870423 | Erasmus Medical Center | Phase 1 |
| Enrolling By Invitation | Simultaneous Hyperpolarized [1-13C]Pyruvate and 18F-FDG PET/MRS in Cancer Patients NCT05396118 | Rigshospitalet, Denmark | Phase 2 |
| Active Not Recruiting | Neuroendocrine Tumors - Patient Reported Outcomes NCT05064150 | University of Iowa | — |
| Recruiting | Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carci NCT05237934 | National Cancer Institute (NCI) | — |
| Recruiting | Lutathera and ASTX727 in Neuroendocrine Tumours NCT05178693 | Imperial College London | Phase 1 |
| Recruiting | Iconographic Registry of Pancreatobiliary Endoscopy Procedures NCT06344507 | IRCCS San Raffaele | — |
| Recruiting | Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Fo NCT05477576 | RayzeBio, Inc. | Phase 3 |
| Completed | Clinical Application of the Prototype J-PET Device NCT06211803 | Jagiellonian University | — |
| Recruiting | 68Ga-HA-DOTATATE Imaging of Suspected Somatostatin Receptor Positive Tumors NCT04888481 | University of Alberta | Phase 2 |
| Recruiting | Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tum NCT05263050 | Fox Chase Cancer Center | Phase 2 |
| Recruiting | Metronomic Temozolomide in Unfit NENs Patients Metronomic Temozolomide in Unfit Patients With Advanced Neuroen NCT05554003 | European Institute of Oncology | Phase 2 |
| Terminated | A Study of Pelcitoclax (APG-1252) in Patients With Neuroendocrine Tumors NCT04893759 | Ascentage Pharma Group Inc. | Phase 1 |
| Completed | Neuroendocrine Neoplasms Methylation Based Classifier - The NEMESIs-study NCT05013957 | University Hospital, Basel, Switzerland | — |
| Withdrawn | Telotristat Ethyl for Reducing Intraoperative Carcinoid Crisis in Patients With Neuroendocrine Tumors NCT04672876 | University of Chicago | Phase 2 |
| Active Not Recruiting | A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies NCT05199272 | 23andMe, Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | HBM4003 Combine With Toripalimab in Patients With Advanced NEN and Other Solid Tumors Study NCT05167071 | Harbour BioMed (Guangzhou) Co. Ltd. | Phase 1 |
| Active Not Recruiting | Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 NCT04919226 | ITM Solucin GmbH | Phase 3 |
| Active Not Recruiting | Targeted Alpha-emitter Therapy of PRRT Naïve and Previous PRRT Neuroendocrine Tumor Patients NCT05153772 | Orano Med LLC | Phase 2 |
| Completed | Optimising Molecular Radionuclide Therapy NCT04922801 | King's College London | — |
| Recruiting | PARP Inhibitor With 177Lu-DOTA-Octreotate PRRT in Patients With Neuroendocrine Tumours NCT05053854 | Peter MacCallum Cancer Centre, Australia | Phase 1 |
| Suspended | Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types NCT05000294 | University of Florida | Phase 1 / Phase 2 |
| Unknown | Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm NCT05113355 | Peking Union Medical College Hospital | Phase 2 |
| Unknown | Chidamide Plus Etoposide and Cisplatin/Carboplatin as First-line Treatment for Extrapulmonary Neuroendocrine C NCT05076786 | Peking Union Medical College Hospital | Phase 2 |
| Unknown | Evaluation of the Diagnostic and Prognostic Role of PET (PET/CT and PET/MRI) in Neuroendocrin Tumors. NCT06159920 | IRCCS San Raffaele | — |
| Recruiting | Assessment of Retreatment With Lutathera® in Patients With New Progression of Intestinal Well-differenciated N NCT04954820 | Institut du Cancer de Montpellier - Val d'Aurelle | Phase 2 |
| Recruiting | CapTemY90 for Grade 2/3 NET Liver Metastases NCT04339036 | Abramson Cancer Center at Penn Medicine | Phase 2 |
| Completed | A Long-term Safety Surveillance Study in Participants Previously Treated With 177Lu-IPN01072 NCT05017662 | Ariceum Therapeutics GmbH | N/A |
| Terminated | Telotristat With Lutathera in Neuroendocrine Tumors NCT04543955 | Lowell Anthony, MD | Phase 2 |
| Completed | Open-label Study of Surufatinib in Japanese Patients NCT05077384 | Hutchmed | Phase 1 / Phase 2 |
| Active Not Recruiting | Combination Immunotherapy in Rare Cancers Under InvesTigation NCT04969887 | Olivia Newton-John Cancer Research Institute | Phase 2 |
| Active Not Recruiting | Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer NCT04848337 | University of Michigan Rogel Cancer Center | Phase 2 |
| Terminated | A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic NCT04644315 | Hoffmann-La Roche | Phase 2 |
| Recruiting | Spanish Series of Patients Treated With the Radionuclide Lutetium177 NCT04949282 | Sociedad Española de Medicina Nuclear e Imagen Molecular | — |
| Completed | The Registry of Oncology Outcomes Associated With Testing and Treatment NCT04028479 | Taproot Health | — |
| Recruiting | Predictive Value of Serum and Tissue Molecular Markers and Imaging Features in the Invasiveness and Prognosis NCT06015802 | Sun Yat-sen University | — |
| Terminated | Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors NCT04579757 | Hutchmed | Phase 1 / Phase 2 |
| Active Not Recruiting | Dual Tracer (68Ga-DOTATATE and 18F-FDG) PET Imaging in G2 & G3 Gastroenteropancreatic Neuroendocrine Tumors NCT04804371 | University Health Network, Toronto | N/A |
| Withdrawn | Prospective Assessment of Patients With Neuroendocrine Tumors and Current or Prior History of Carcinoid Syndro NCT04713202 | Chandrikha Chandrasekhara | Phase 2 |
| Completed | A Diagnostic Imaging Study of 64Cu-SARTATE Using PET on Patients With Known or Suspected Neuroendocrine Tumors NCT04438304 | Clarity Pharmaceuticals Ltd | Phase 2 |
| Active Not Recruiting | A Trial of Cabozantinib in Patients With Advanced, Low Proliferative NEN G3 NCT04524208 | Karsten Gavenis | Phase 2 |
| Withdrawn | Study of MIBG-I131 in Patients With Well Differentiated Neuroendocrine Tumors NCT04831567 | AC Camargo Cancer Center | Phase 2 |
| Recruiting | 18F-DOPA II - PET Imaging Optimization NCT04706910 | University of Alberta | Phase 3 |
| Completed | 68Ga-DOTA-MGS5 PET/CT in Patients With Advanced Neuroendocrine Tumours NCT06155994 | Medical University Innsbruck | Phase 1 / Phase 2 |
| Completed | Asian Investigation of Lanreotide Autogel® in the Management of GEP-NETs NCT04696042 | Asan Medical Center | — |
| Unknown | Gallium-68 NODAGA-JR11 PECT/CT in Neuroendocrine Tumors NCT04897542 | First Affiliated Hospital of Fujian Medical University | EARLY_Phase 1 |
| Terminated | Natural History Study of Children and Adults With Neuroendocrine Neoplasms (NEN)s NCT04488263 | National Cancer Institute (NCI) | — |
| Unknown | Using 18F- FDG,18F-DOPA and 68Ga-DOTATATE PET/CT in Detection and Evaluation of Response in Patients With NET NCT04622631 | Dr. Nayruz Knaana | — |
| Active Not Recruiting | Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma NCT04291885 | Melanoma and Skin Cancer Trials Limited | Phase 2 |
| Completed | Imaging Properties of PET Radiotracer [18F]3F-PHPG in Patients With Neuroendocrine Tumors NCT04510311 | University of Michigan Rogel Cancer Center | EARLY_Phase 1 |
| Completed | Al18F-NOTA-octreotide PET Imaging in Neuroendocrine Tumors NCT04552847 | Universitaire Ziekenhuizen KU Leuven | Phase 2 / Phase 3 |
| Unknown | Impact of Peptides and Chelators on Somatostatin Receptor Antagonists NCT04491851 | Peking Union Medical College Hospital | Phase 2 |
| Withdrawn | Open Label Study to Analyze the Effect of Telotristat Ethyl on Weight Regulation/Gain NCT04034745 | Andrew Hendifar, MD | — |
| Active Not Recruiting | Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics NCT04584008 | Peking University | N/A |
| Recruiting | Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN) NCT04464122 | University of Roma La Sapienza | — |
| Active Not Recruiting | Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That NCT04544098 | Memorial Sloan Kettering Cancer Center | EARLY_Phase 1 |
| Unknown | Financial Toxicity and Patient-Reported Outcomes in GEP-NEN During Treatment NCT05334290 | Massimo Falconi | — |
| Withdrawn | Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents NCT03923257 | Sue O'Dorisio | Phase 1 / Phase 2 |
| Completed | Cohort of Well-differentiated Grade 3 Neuroendocrine Digestive Tumors NCT04365023 | Assistance Publique - Hôpitaux de Paris | — |
| Recruiting | Phase II Clinical Study of Leflunomide in the Treatment of MEN-1 Neuroendocrine Tumor NCT06540937 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 |
| Completed | Nutrition in Gastrointestinal Tumors NCT04476082 | University Medicine Greifswald | — |
| Unknown | A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NCT04427787 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Phase 2 |
| Unknown | Registry on NEN Patients and COVID-19 NCT04444401 | European Institute of Oncology | — |
| Completed | 18F-AmBF3-TATE PET/CT for Imaging NET Patients NCT04207762 | British Columbia Cancer Agency | — |
| Recruiting | Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors NCT04074135 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Multicenter Retrospective Database on Prognostic and Predictive Factors in Patients With Neuroendocrine Tumors NCT05168631 | Latin American Cooperative Oncology Group | — |
| Unknown | Portal Vein Resection in Pancreatic Neuroendocrine Tumours NCT04336839 | Royal Free Hospital NHS Foundation Trust | — |
| Completed | 177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours NCT04375267 | Vastra Gotaland Region | Phase 1 |
| Unknown | Developing a Method Using PET-MR to Improve Staging and Monitoring of Neuroendocrine Tumor NCT04154241 | Tel-Aviv Sourasky Medical Center | N/A |
| Completed | Neoadjuvant PRRT With 177Lu-DOTATATE Followed by Surgery for Resectable PanNET NCT04385992 | IRCCS San Raffaele | Phase 2 |
| Recruiting | A Study to Evaluate a New Way to Identify/Diagnose Tumours With Somatostatin Receptors Using [68]Ga-HA-DOTATAT NCT03145857 | AHS Cancer Control Alberta | Phase 1 / Phase 2 |
| Withdrawn | Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Prima NCT04276597 | Excel Diagnostics and Nuclear Oncology Center | Phase 2 |
| Unknown | Applying PET/MR in Neuroendocrine Tumors - Imaging Dynamic Processes in Both Modalities NCT04152928 | Tel-Aviv Sourasky Medical Center | N/A |
| Terminated | 18F-MFBG PET Imaging of the Norepinephrine Transporter in Neural Crest and Neuroendocrine Tumors NCT04258592 | Universitaire Ziekenhuizen KU Leuven | Phase 1 |
| Recruiting | 68Ga-DOTA-TATE PET/CT Imaging in NETs NCT04847505 | Centre de recherche du Centre hospitalier universitaire de Sherbrooke | Phase 3 |
| Completed | Cabozantinib and Nivolumab for Carcinoid Tumors NCT04197310 | Dana-Farber Cancer Institute | Phase 2 |
| Recruiting | A Phase II Study on Adjuvant Vaccination with Dendritic Cells Loaded with Autologous Tumor Homogenate in Resec NCT04166006 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Phase 2 |
| Recruiting | Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers NCT03935893 | Udai Kammula | Phase 2 |
| Completed | Gallium-68 Labeled LM3 PET/CT in Neuroendocrine Tumors NCT04318561 | Peking Union Medical College Hospital | Phase 1 / Phase 2 |
| Unknown | Dynamic Whole Body Positron Emission Tomography/Computed Tomography Imaging NCT04017104 | British Columbia Cancer Agency | — |
| Recruiting | Clinico-biological Database in Patients Treated With Metabolic Radiotherapy in the Nuclear Medicine Department NCT04104529 | Institut du Cancer de Montpellier - Val d'Aurelle | N/A |
| Completed | Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) NCT03980925 | Grupo Espanol de Tumores Neuroendocrinos | Phase 2 |
| Unknown | Early Identification of Cardiac Involvement in Patients With Carcinoid: Clinical and Prognostic Implications NCT06321692 | European Institute of Oncology | N/A |
| Completed | SUV on 68Ga-DOTATATE PET/CT and Ki-67 Index in Neuro-Endocrine Tumors NCT02840149 | Jewish General Hospital | Phase 3 |
| Terminated | Cryoablation of Bone Metastases From Endocrine Tumors NCT03986593 | Instituto do Cancer do Estado de São Paulo | N/A |
| Terminated | Assessment of a Serious Illness Conversation Guide (SICG) in Advanced Gastro-Intestinal Cancers NCT04077372 | Stanford University | N/A |
| Completed | Endoscopic Ultrasound-guided RadioFrequency Ablation for the Treatment Pancreatic NeuroEndocrine Neoplasms NCT03834701 | Catholic University of the Sacred Heart | N/A |
| Unknown | Resection of Metastatic Pancreatic Neuroendocrine Tumors After Induction System Treatment NCT04066322 | Fudan University | — |
| Withdrawn | Study to Assess the Use of Lanreotide Autogel® 120 mg in Patients With Locally Advanced or Metastatic Gastroen NCT03895463 | Ipsen | — |
| Unknown | Image-Enhanced Endoscopy in the Gastrointestinal Tract NCT04085211 | King's College Hospital NHS Trust | — |
| Unknown | PFS and OS of Patients With Advanced Neuroendocrine Cancer (NEN) After Systemic Treatment NCT04331912 | University of Warmia and Mazury | — |
| Unknown | A Study to Evaluate the Value of Circulating Tumour DNA in Follow-up of Patients With an Advanced Gastroentero NCT05268952 | University Hospital, Antwerp | N/A |
| Unknown | Study of the Diagnostic Value of Hybrid PET/MR and PET/CT in Neuroendocrine Diseases and Tumor Induced Osteoma NCT04045834 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | — |
| Completed | Al18F-NOTA-octreotide PET Imaging of the Somatostatin Receptor in Neuroendocrine Tumors NCT03883776 | Universitaire Ziekenhuizen KU Leuven | Phase 1 |
| Completed | 68Ga-DOTATATE PET for Management of Neuroendocrine Tumors NCT03873870 | University Health Network, Toronto | N/A |
| Completed | Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression NCT03870399 | AC Camargo Cancer Center | Phase 2 |
| Completed | A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer o NCT03910660 | BioXcel Therapeutics Inc | Phase 1 / Phase 2 |
| Completed | TheraSphere Selective Internal Radiation Therapy (SIRT) as Treatment for Neuroendocrine Tumours With Liver Met NCT04362436 | Imperial College London | Phase 2 |
| Completed | The Patient's Journey - the Time to Final Diagnosis in Patients With SiNET NCT03840720 | Vastra Gotaland Region | — |
| Unknown | Personalized CAPTEM Radiopeptide Therapy of Advanced, Non-resectable Neuroendocrine Cancer NCT04194125 | University of Warmia and Mazury | Phase 2 |
| Active Not Recruiting | Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advance NCT03728361 | Dwight Owen | Phase 2 |
| Active Not Recruiting | Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors NCT03600233 | TaiRx, Inc. | Phase 2 |
| Completed | Evaluating an Amino Acid Based Medical Food w/ Diarrhea in Carcinoid Syndrome & Other NETs NCT03722511 | Lowell Anthony, MD | Phase 2 |
| Unknown | Neuroendocrine Tumors of Old Patients in the West of France NCT03749681 | University Hospital, Brest | — |
| Active Not Recruiting | Post-Authorization Long-Term Safety Study of LUTATHERA NCT03691064 | Advanced Accelerator Applications | — |
| Terminated | A Study to testABI-009 in Patients With Metastatic, Unresectable, Low or Intermediate Grade Neuroendocrine Tum NCT03670030 | Robert Ramirez | Phase 2 |
| Completed | MGMT-NET: O6-methylguanine-DNA Methyltransferase (MGMT) Status in Neuroendocrine Tumors: Predictive Factor of NCT03217097 | Hospices Civils de Lyon | N/A |
| Terminated | Selective Intra-arterial Injection of PRRT in Neuroendocrine Tumor Patients With Liver Metastases NCT03724409 | Sandeep Laroia | EARLY_Phase 1 |
| Recruiting | Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoan NCT03412877 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Imaging of Patients With Known or Suspected Somatostatin Receptor Positive Neuroendocrine Tumors Using Cu64-DO NCT03673943 | Radiomedix, Inc. | Phase 3 |
| Completed | Intra-arterial Lutetium-177-dotatate for Treatment of Patients With Neuro-endocrine Tumor Liver Metastases NCT03590119 | Marnix Lam | Phase 2 / Phase 3 |
| Completed | Perception of Information and Quality of Life in Neuroendocrine Tumour on Lanreotide Autogel NCT03562091 | Ipsen | — |
| Completed | Whole Body Dynamic 68Ga-DOTATOC PET/CT in Neuroendocrine Tumors NCT03576040 | University Hospital, Brest | — |
| Active Not Recruiting | DOTATOC PET/CT for Imaging NET Patients NCT03583528 | British Columbia Cancer Agency | — |
| Unknown | Peptide Receptor Radionuclide Therapy (PRRT) in Tumors With High Expression of Somatostatin Receptors (Phase 2 NCT04790708 | University Hospital of Ferrara | N/A |
| Unknown | DEBOXA for Inoperable NET Liver Metastases NCT03881306 | Xiangya Hospital of Central South University | Phase 1 / Phase 2 |
| Terminated | Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors NCT03420521 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Unknown | Volumetric Imaging Follow up of Patients With Liver Metastases of Small Intestinal Neuroendocrine Tumors (NETs NCT03689231 | Hospices Civils de Lyon | — |
| Unknown | Efficacy and Safety of 177Lu-Dotatate PRRT in Metastatic GEP-NEN Patients NCT03422029 | Peking University | Phase 2 |
| Recruiting | SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry NCT03452774 | Massive Bio, Inc. | — |
| Completed | Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors NCT03290079 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Terminated | Entinostat Neuroendocrine (NE) Tumor NCT03211988 | Antonio Fojo | Phase 2 |
| Completed | PET/CT Imaging of Angiogenesis in Patients With Neuroendocrine Tumors Using 68Ga-NODAGA-E[c(RGDyK)]2 NCT03271281 | Rigshospitalet, Denmark | Phase 2 |
| Terminated | Pembrolizumab for the Treatment of Recurrent High Grade Neuroendocrine Carcinoma NCT03190213 | University of Utah | Phase 2 |
| Completed | Avelumab in G2-3 NET NCT03278379 | Sunnybrook Health Sciences Centre | Phase 2 |
| Active Not Recruiting | Gallium 68 Pentixafor in Patients With Neuroendocrine Tumors NCT03335670 | Yusuf Menda | EARLY_Phase 1 |
| Completed | PET/CT Imaging of uPAR-expression in Patients With Neuroendocrine Tumors Using 68Ga-NOTA-AE105 NCT03278275 | Rigshospitalet, Denmark | Phase 2 |
| Recruiting | Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma NCT03206060 | National Cancer Institute (NCI) | Phase 2 |
| Completed | A Study to Evaluate the Value of Circulating Tumour DNA in Follow-up of Patients With an Advanced Gastroentero NCT05255133 | Universiteit Antwerpen | N/A |
| Completed | Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC) NCT03273712 | University of Iowa | Phase 2 |
| Completed | A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Ac NCT03289741 | Memorial Sloan Kettering Cancer Center | Phase 4 |
| Unknown | Study to Compare Capecitabine Combined With Dacarbazine(CAPDTIC) Versus Capecitabine Combined Temozolomide(CAP NCT03279601 | Peking University | Phase 2 |
| Unknown | Explore the Clinical Value of 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in Neuroendocrine Neoplasms NCT03288597 | Peking University | — |
| Terminated | Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs NCT02943733 | University of Wisconsin, Madison | Phase 1 |
| Unknown | Psychosocial Screening for Neuroendocrine Tumor Patients NCT03372356 | Peking University | — |
| Terminated | Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Live NCT02859064 | SCRI Development Innovations, LLC | Phase 2 |
| Completed | Study to Evaluate the Use of Resources and the Costs Associated With Carcinoid Syndrome (CS) in Patients With NCT03220087 | Ipsen | — |
| Unknown | Study of Lanreotide in Metastatic or Recurrent Grade I-II Hindgut NET NCT03083210 | Samsung Medical Center | Phase 4 |
| Completed | 18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety NCT03042416 | University of Alberta | Phase 3 |
| Completed | Octreotide LAR in the Induction of Immunologic Response in NENs Patients NCT04129255 | National Cancer Institute, Naples | Phase 2 |
| Completed | TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors NCT03079440 | Asan Medical Center | Phase 2 |
| Unknown | Biomarker Study in Pancreatic Neuroendocrine Tumours NCT03130205 | Uppsala University | — |
| Unknown | Treatment Using 177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine Tumors NCT03478358 | Peking Union Medical College Hospital | Phase 1 |
| Unknown | 177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine Tumors NCT03308682 | Peking Union Medical College Hospital | Phase 1 |
| Completed | Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lun NCT03095274 | Grupo Espanol de Tumores Neuroendocrinos | Phase 2 |
| Completed | Study of JS001 in Patients With Advanced Neuroendocrine Tumors NCT03167853 | Peking University | Phase 1 |
| Completed | Switching From Octreotide to Lanreotide - A Look Back at Patients With Neuroendocrine Tumors NCT03112694 | Ipsen | — |
| Completed | Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Can NCT03037385 | Hoffmann-La Roche | Phase 1 / Phase 2 |
| Terminated | Fosbretabulin With Everolimus in Neuroendocrine Tumors With Progression NCT03014297 | Lowell Anthony, MD | Phase 1 |
| Terminated | Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs NCT02592707 | Ipsen | Phase 1 / Phase 2 |
| Completed | A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors NCT03070301 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | Beta- Probe and Surgery in GEP NET: Evaluation of a New Probe NCT04296149 | European Institute of Oncology | Phase 2 |
| Active Not Recruiting | Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients NCT03049189 | ITM Solucin GmbH | Phase 3 |
| Completed | Investigation of the Effects of Diet on the Measurement of Plasma Chromogranin in NET Patients NCT03288402 | University Hospitals Coventry and Warwickshire NHS Trust | N/A |
| Active Not Recruiting | Nonfunctioning Small (≤2 cm) Neuroendocrine Pancreatic Incidentaloma NCT03022188 | Société Française d'Endoscopie Digestive | — |
| Completed | PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Ca NCT02936323 | Tarveda Therapeutics | Phase 1 / Phase 2 |
| Completed | Circulating Tumor Cells and Tumor DNA in HCC and NET NCT02973204 | University of Aarhus | — |
| Completed | A Study of Pembrolizumab in Patients With Neuroendocrine Tumors NCT02939651 | Fox Chase Cancer Center | Phase 2 |
| Completed | The Indol Profile; Exploring the Metabolic Profile of Neuroendocrine Tumors NCT02815969 | University Medical Center Groningen | — |
| Active Not Recruiting | Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors NCT02743741 | University Health Network, Toronto | N/A |
| Completed | Validation of 99mTc- EDDA - HYNIC -TOC Kits for Diagnosis of Neuroendocrine Tumors NCT02691078 | Latin American Cooperative Oncology Group | Phase 2 |
| Unknown | Identification of Biomarker Profiles GEP-NEN Patients NCT02838862 | University Hospital Schleswig-Holstein | — |
| Completed | Study to Measure the Safety of 68Ga-DOTA-TATE PET/CT in the Diagnosis of Tumors Expressing Somatostatin Recept NCT02810600 | Centre de recherche du Centre hospitalier universitaire de Sherbrooke | — |
| Withdrawn | Endoscopic Ultrasound Guided Radiofrequency Ablation (EUS-RFA) for Small Benign Pancreatic Tumors NCT02882503 | National Taiwan University Hospital | N/A |
| Active Not Recruiting | Optimizing the Interval Between Cycles of PRRT with 177lu-dotatate in Sstr2 Positive Tumors NCT03454763 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Phase 2 |
| Completed | Diagnosis and Staging of Neuroendocrine Tumors (NETs) Utilizing 68Ga-DOTATOC PET/CT Scan NCT03136328 | Montefiore Medical Center | Phase 3 |
| Completed | Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors NCT02611024 | PharmaMar | Phase 1 / Phase 2 |
| Active Not Recruiting | Personalized PRRT of Neuroendocrine Tumors NCT02754297 | CHU de Quebec-Universite Laval | Phase 2 |
| Unknown | The MetNET-2 Trial NCT02823691 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | EARLY_Phase 1 |
| Active Not Recruiting | Study of Recombinant Adenovirus AdVince in Patients With Neuroendocrine Tumors; Safety and Efficacy NCT02749331 | Uppsala University | Phase 1 / Phase 2 |
| Terminated | Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation Optimisation NCT04140409 | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Phase 4 |
| Completed | Heterogeneity of Metastatic Neuroendocrine Tumors as Determined With 18F-dihydroxyphenylalanine-PET /CT, a Ret NCT02646644 | University Medical Center Groningen | — |
| Completed | Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors NCT02588170 | Hutchison Medipharma Limited | Phase 3 |
| Completed | Phase III Study of Surufatinib in Treating Advanced Pancreatic Neuroendocrine Tumors NCT02589821 | Hutchison Medipharma Limited | Phase 3 |
| Active Not Recruiting | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (T NCT02568267 | Hoffmann-La Roche | Phase 2 |
| Completed | Theranostics of Radiolabeled Somatostatin Antagonists 68Ga-DOTA-JR11 and 177Lu-DOTA-JR11 in Patients With Neur NCT02609737 | Memorial Sloan Kettering Cancer Center | N/A |
| Completed | Lenvatinib Efficacy in Metastatic Neuroendocrine Tumors NCT02678780 | Grupo Espanol de Tumores Neuroendocrinos | Phase 2 |
| Completed | Peptide Receptor Radionuclide Therapy With 177Lu-Dotatate Associated With Metronomic Capecitabine In Patients NCT02736500 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Phase 1 / Phase 2 |
| Completed | Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors NCT02441062 | Sue O'Dorisio | Phase 2 |
| Completed | 5-HIAA in Urine Versus 5-HIAA in Plasma Patients With a Serotonin Producing Neuroendocrine Tumor' NCT02507908 | University Medical Center Groningen | — |
| Completed | RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based NCT02489903 | EpicentRx, Inc. | Phase 2 |
| Completed | An Imaging Study of 64Cu-SARTATE Using Positron Emission Tomography in Patients With Neuroendocrine Tumours NCT04440956 | Clarity Pharmaceuticals Ltd | EARLY_Phase 1 |
| Completed | Pharmaco-immunological Study of Interferon-alpha and Metronomic Cyclophosphamide Association in Neuroendocrine NCT02838342 | Centre Hospitalier Universitaire de Besancon | Phase 2 |
| Completed | A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pan NCT02402062 | Grupo Espanol de Tumores Neuroendocrinos | Phase 2 |
| Unknown | Recombinant Anti-tumor and Anti-virus Protein for Injection to Treat Advanced Neuroendocrine Tumors NCT02455596 | The Affiliated Hospital of the Chinese Academy of Military Medical Sciences | Phase 2 |
| Terminated | Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-G NCT02315625 | National Cancer Institute (NCI) | Phase 2 |
| No Longer Available | Gallium-68 DOTATOC for Management of Neuroendocrine Tumors NCT02375464 | Northwell Health | — |
| Completed | Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1 NCT02355535 | Vanquish Oncology, Inc. | Phase 1 |
| Completed | 18F-MFBG Imaging for Evaluation of Neuroendocrine Malignancies NCT02348749 | Memorial Sloan Kettering Cancer Center | Phase 1 / Phase 2 |
| Completed | Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours NCT02299089 | Camurus AB | Phase 2 |
| Terminated | 68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs NCT02359500 | Lale Kostakoglu | Phase 1 |
| Completed | Rollover Protocol for Subjects Who Have Responded on Study 4218s - A Phase 2 Study NCT02279602 | Mateon Therapeutics | Phase 2 |
| Completed | A Real-world Comparison of FNB and FNA in IHC-required Lesions. NCT05565066 | Huazhong University of Science and Technology | — |
| Completed | Phase Ib/II Study of Sulfatinib in Treating Advanced Neuroendocrine Tumors NCT02267967 | Hutchison Medipharma Limited | Phase 1 |
| Completed | Sequentiality of Everolimus and STZ-5FU in Advanced Pancreatic Neuroendocrine Tumor NCT02246127 | Grupo Espanol de Tumores Neuroendocrinos | Phase 3 |
| Recruiting | Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer NCT02174549 | Teclison Ltd. | Phase 1 / Phase 2 |
| Completed | PET-CT Imaging of Neuro-endocrine Tumors and Preliminary Clinical Evaluation NCT02134639 | University Hospital, Bordeaux | — |
| Completed | A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Bi NCT02132468 | Mateon Therapeutics | Phase 2 |
| Completed | Evaluation of [18F]Fluoroethyl Triazole Labelled [Tyr3]-Octreotate Analogues for the Imaging of Neuroendocrine NCT06456723 | Imperial College London | Phase 1 / Phase 2 |
| Unknown | 68Ga-DOTATATE PET/CT in Neuroendocrine Tumor NCT04041882 | Peking Union Medical College Hospital | EARLY_Phase 1 |
| Completed | Gastroenteral-Pancreatic Neuroendocrine Tumors in Taiwan NCT02102893 | National Health Research Institutes, Taiwan | — |
| Completed | Holmium-166-radioembolization in NET After Lutetium-177-dotatate; an Efficacy Study NCT02067988 | UMC Utrecht | Phase 2 |
| Terminated | Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE in Advanced Gastro-entero Pancreatic Neuroend NCT02489604 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Phase 2 |
| Recruiting | Integrated Cancer Repository for Cancer Research NCT02012699 | University of Nebraska | — |
| Completed | Efficacy of 177-Lu-DOTA 0, Tyr 3 Octreotate NCT02125474 | Instituto Nacional de Cancerologia, Columbia | N/A |
| Completed | Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors NCT01967537 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Prospective Comprehensive Molecular Profiling In Neuroendocrine Tumors NCT02586844 | University Health Network, Toronto | — |
| Completed | Impact of 68Ga-DOTATATE PET/CT on the Management of Neuroendocrine Tumors: The Referring Physician's Perspecti NCT01873248 | Jonsson Comprehensive Cancer Center | EARLY_Phase 1 |
| Unknown | 124I-MIBG Tracer Evaluation of Myocardial Sympathetic Denervation and Assessment of Neuroendocrine Tumors. NCT01931488 | Tel-Aviv Sourasky Medical Center | Phase 2 |
| Unknown | A Clinical Trial With a New Needle Device Comparing Two Needles for EUS_FNA of Solid Lesions. NCT02246322 | Istituto Clinico Humanitas | N/A |
| Terminated | Systemic Therapy With or Without Upfront Transarterial Embolization for Inoperable Liver Metastasis of Neuroen NCT01755182 | National Cancer Institute, Naples | Phase 3 |
| Completed | Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored NCT01794793 | RECORDATI GROUP | Phase 4 |
| Completed | Clinical Relevance of the Salvage Treatment for Colorectal Neuroendocrine Tumors NCT06143605 | Yanhong Deng | — |
| Unknown | Treatment of Neuroendocrine Tumors (NETs) With Combination of Everolimus and Radiolabeled Somatostatin Analogu NCT03629847 | King Faisal Specialist Hospital & Research Center | Phase 1 / Phase 2 |
| Completed | Everolimus After (Chemo)Embolization for Liver Metastases From Digestive Endocrine Tumors NCT01678664 | Federation Francophone de Cancerologie Digestive | Phase 2 |
| Terminated | Phase 2a Desipramine in Small Cell Lung Cancer and Other High-Grade Neuroendocrine Tumors NCT01719861 | Joel Neal | Phase 2 |
| Completed | Proton Boost for Locally Advanced HEAD AND NECK TUMORS NCT03183271 | CNAO National Center of Oncological Hadrontherapy | N/A |
| Completed | Evaluate Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs NCT01590199 | Novartis Pharmaceuticals | Phase 1 |
| Completed | Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Ad NCT01524783 | Novartis Pharmaceuticals | Phase 3 |
| Completed | Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors NCT01619865 | Sue O'Dorisio | Phase 1 / Phase 2 |
| Completed | Preoperative Imaging in Patients With Small Bowel Neuroendocrine Tumors NCT05246319 | Laurent BRUNAUD | — |
| Completed | Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases NCT01469572 | Emory University | Phase 1 |
| Unknown | Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Ca NCT01744249 | Grupo Espanol de Tumores Neuroendocrinos | Phase 2 / Phase 3 |
| Completed | A Multicenter Study Evaluating Efficacy and Safety of 177Lu-DOTA-TATE Based on Kidney-Dosimetry in Patients Wi NCT01456078 | Lund University Hospital | Phase 2 |
| Completed | Dose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs) NCT01364415 | Novartis Pharmaceuticals | Phase 1 |